Germinal center (GC) B cells feature repression of many gene enhancers to establish their characteristic transcriptome. Here we show that conditional deletion of Lsd1 in GCs significantly impaired GC formation, associated with failure to repress immune synapse genes linked to GC exit, which are also direct targets of the transcriptional repressor BCL6. We found that BCL6 directly binds LSD1 and recruits it primarily to intergenic and intronic enhancers. Conditional deletion of Lsd1 suppressed GC hyperplasia caused by constitutive expression of BCL6 and significantly delayed BCL6-driven lymphomagenesis. Administration of catalytic inhibitors of LSD1 had little effect on GC formation or GC-derived lymphoma cells. Using a CRISPR-Cas9 domain screen, we found instead that the LSD1 Tower domain was critical for dependence on LSD1 in GC-derived B cells. These results indicate an essential role for LSD1 in the humoral immune response, where it modulates enhancer function by forming repression complexes with BCL6.
G erminal centers (GCs) are dynamic structures induced by T cell-dependent antigen stimulation during the humoral immune response, to enable immunoglobulin affinity maturation 1 . GC B cells manifest a unique phenotype that includes features such as massive proliferation and tolerance of genomic damage occurring as a byproduct of somatic hypermutation 2 . The transition from resting, quiescent B cells to GC B cells requires multilayered chromatin reorganization and the coordinated action of multiple transcription factors [3] [4] [5] [6] [7] [8] [9] [10] .
One of the dominant regulatory mechanisms involved in setting up the GC B cell phenotype is the transient transcriptional repression of gene promoters and enhancers involved in terminal differentiation, as well as genes involved in chemotaxis, DNA damage and proliferation checkpoints. Histone-modifying enzymes such as CREBBP, EP300 and KMT2D all play important roles in regulating the switching of enhancers on and off in GC B cells through histone 3 lysine 27 (H3K27) acetylation and histone 3 lysine 4 (H3K4) monomethylation, respectively [7] [8] [9] [10] . The Polycomb protein EZH2 mediates promoter poising by creating bivalent chromatin domains at checkpoint and differentiation genes 3, 4 . The transcriptional repressor BCL6 helps to coordinate enhancer and promoter pausing through the recruitment of corepressor proteins 6 . The proliferative and genetically unstable nature of GC B cells makes them prone to malignant transformation. Most B cell lymphomas accordingly arise from GC B cells and often share dependence on the same transcriptional regulators (for example, BCL6).
Recent studies of gene enhancer chromatin during the GC reaction have unveiled a specific pattern of enhancer erasing and rewriting involving loss of H3K4me1/2 in about 2,800 sites 5 , suggesting that histone demethylases probably contribute to the GC reaction. The first histone demethylase to be discovered, LSD1 (lysine-specific demethylase 1A; encoded by KDM1A in humans and Kdm1a in mice), specifically catalyzes demethylation of H3K4me1/2 (ref. 11 ). Lsd1 deletion results in developmental arrest and is lethal at early embryonic stages [12] [13] [14] . However, many of its cell-contextspecific functions remain unknown. It was recently shown that inducible deletion of Lsd1 in early hematopoietic stem cells perturbs differentiation and terminal blood cell maturation, resulting in pancytopenia 15 . LSD1 overexpression has been observed in many tumor types, such as bladder, colorectal, breast and small cell lung cancer, and high LSD1 expression may function as biomarker for disease aggressiveness. In acute myeloid leukemia, LSD1 was shown to maintain leukemic stem cells, and LSD1 inhibition was shown to promote differentiation 16 . Here we explore the role of LSD1 in GC formation and the humoral immune response.
Results
LSD1 is required for the humoral immune response. To identify histone demethylases that might repress enhancers in GC B cells, we first mined RNA-sequencing (RNA-seq) data profiles to determine expression of the two known families of H3K4 demethylases, Articles NATURe ImmUNoLoGy KDM1 and KDM5, in naïve B (NB) cells versus GC B cells in humans and mice. LSD1 was the most consistently upregulated from NB cells to GC B cells ( Fig. 1a and Supplementary Fig. 1a ). We confirmed this result using qPCR in purified human NB versus GC B cells, where we observed two-fold LSD1 induction, along with the expected upregulation of BCL6 and AICDA ( Fig. 1b and Supplementary Fig. 1b ), and LSD1 immunoblots showed a similar degree of upregulation ( Fig. 1c ). Immunohistochemistry (IHC) of tonsil sections showed higher LSD1 expression in GCs, especially in the proliferative dark zone ( Supplementary Fig. 1c ). LSD1 expression was maintained in post-GC B cells such as plasmacytes and memory B cells ( Supplementary Fig. 1d ).
We next asked whether LSD1 is required for the development of GCs. We crossed conditional Lsd1 fl/fl mice 15 with the Cγ1-Cre strain, which expresses Cre recombinase in GC B cells. Next we immunized Lsd1 fl/fl , Cγ1-Cre Lsd1 fl/+ or Cγ1-Cre Lsd1 fl/fl conditional mice with T cell-dependent antigen (sheep red blood cells (SRBCs)) to induce GC formation and analyzed the composition of their spleens 10 d later. Conditional homozygous and heterozygous Lsd1 deletion in GCs resulted in a marked and gene dose-dependent reduction in GCs, as shown by IHC using peanut agglutinin (PNA) ( Fig. 1d,e ), without any perturbation of B cell follicular structure, as shown by B220 IHC ( Supplementary  Fig. 1e ). The numbers of splenic GCs formed were markedly reduced in Lsd1-deficient mice ( Supplementary Fig. 1f ). Concordant with the reduction in GC B cells, we observed a dose-dependent reduction in Ki67 + (Fig. 1d,e ) and bromodeoxyuridine-positive (BrdU + ) cells after injection of BrdU 4 h prior to euthanasia at day 10 post antigen challenge ( Fig. 1d,e ).
Using flow cytometry staining to quantify relative abundance of GC B cells (Fas + GL7 + B220 + and Fas + CD38 lo B220 + ), we observed dose-dependent and significant loss of GC B cells in Lsd1-deficient mice (Fig. 1f,g) . Lsd1 locus amplification in sorted GC B cells from Lsd1 fl/fl or Cγ1-Cre Lsd1 fl/fl mice confirmed loss of LSD1 in these residual cells ( Supplementary Fig. 1g ) and prompted us to monitor the GC reaction in Lsd1 fl/fl versus Cγ1-Cre Lsd1 fl/fl mice every 2 d, starting 4 d post antigen challenge. Although control Lsd1 fl/fl animals showed robust GC formation at days 6, 8 and 10, Cγ1-Cre Lsd1 fl/fl mice showed a severe loss in their ability to mount a full-blown GC response, and most of the incipient GC B cells were cleared within 10 d post antigen challenge ( Supplementary Fig. 1h ,i). Thus, LSD1 is required to support the expansion of newly forming GCs.
To assess the impact of Lsd1 loss of function on immunoglobulin affinity maturation, we challenged Lsd1 fl/fl and Cγ1-Cre Lsd1 fl/fl mice with NP 30 -CGG, followed by a boost immunization at day 21. Measurement of high-affinity serum antibodies (binding NP 7 -BSA) or low-affinity serum antibodies (binding NP 30 -BSA) by ELISA revealed significantly lower titers of high-affinity IgG1 (P = 0.0007) in conditional Lsd1-deficient mice ( Supplementary Fig. 1j ). The ratio of high-affinity to low-affinity IgG1, IgG2b and IgG3 circulating antibody titers was also reduced ( Supplementary Fig. 1k ). Additionally, long-lived plasma cells secreting class-switched anti-NP immunoglobulins were markedly reduced in Cγ1-Cre Lsd1 fl/fl mice versus Lsd1 fl/fl mice at 40 d after their primary immunization, as shown using ELISpot ( Supplementary Fig. 1l ).
These results raised the possibility that Lsd1 deletion earlier in B cell development might force premature differentiation into plasma cells or extrafollicular plasmablasts. To investigate this possibility, we crossed conditional Lsd1 fl/fl mice 15 with Cd19-Cre mice expressing Cre recombinase in all B lymphocytes. These animals also manifested significantly reduced GC formation ( Supplementary  Fig. 2a ,b) and significant depletion of GC B cells ( Supplementary  Fig. 2c-e ). However, we did not observe spontaneous differentiation of B cells into downstream lineages such as plasmacytes (CD138 + B220 -) or plasmablasts (CD138 + , κ + , B220 -) in the absence of Lsd1 ( Supplementary Fig. 2f ,g). Taken together, these results indicate that LSD1 plays an important role in GC formation and immunoglobulin affinity maturation.
LSD1 is a key mediator of the GC transcriptional program.
To identify the LSD1-regulated transcriptome in GC B cells, we performed RNA-seq analysis of sorted GC B cells from three independent Lsd1 fl/fl or Cγ1-Cre Lsd1 fl/fl mice. We observed that 120 genes were significantly differentially expressed in Lsd1-deficient GC B cells (false discovery rate (FDR) < 0.05, fold change > 1.5), the majority of which were upregulated (n = 87, Fig. 2a ), including canonical plasma and memory cell differentiation genes such as Irf4 and Prdm1, as well as Cd80, which is important for B cell induction of follicular helper T cells 17 ; Cxcr3, which plays a critical role in plasma cell differentiation 18 ; and Stat4, which induces plasma cell differentiation in GC B cells downstream of IL-12 (ref. 19 ). Lsd1 loss of function also yielded upregulation of Gpr132, a gene that suppresses the proliferation of B cells 20 .
ATAC-seq in sorted viable GC B cells from Cγ1-Cre Lsd1 fl/fl or Lsd1 fl/fl mice revealed 733 loci that gained accessibility and 314 with reduced accessibility (FDR < 0.05, Fig. 2b ,c). Loci that gained chromatin accessibility were mostly localized in intergenic and intronic regions (77%, Fig. 2d ). Examples of genes linked to loci that gained accessibility included Prdm1 (FDR = 0.032), Cd38, which encodes a marker induced in memory B cells (intronic, FDR = 0.00045) and Stat4 (intronic, FDR = 0.02) ( Fig. 2e ). Notably, gene transcripts linked to a gain in chromatin accessibility in Lsd1-deficient cells were significantly upregulated ( Fig. 2f ), whereas genes associated with loci with unaltered or reduced chromatin accessibility did not manifest significant differential expression. Along these lines, we observed significant enrichment for genes with increased chromatin accessibility (n = 610 genes) among those genes induced in Lsd1deficient GC B cells ( Fig. 2g ).
Pathway analysis using curated gene sets linked to normal and malignant B cell functions revealed significant enrichment for genes linked to silenced or poised enhancers in the transition from NB cells to GC B cells ( Fig. 2h) , as well as genes involved in the terminal differentiation of GC B cells into plasma cells and memory B cells ( Fig. 2h ). Also enriched were direct target genes of CTCF and EP300 and, most notably, genes directly bound and repressed by BCL6. In an orthogonal analysis, we observed significant enrichment for genes repressed by BCL6 through promoter or enhancer binding among genes that are upregulated upon Lsd1 deletion in GC B cells 6 ( Fig. 2i ). BCL6 contains two repressor domains, and Lsd1-deficient GC B cells showed upregulation of genes repressed by BCL6, specifically through its RD2 repression domain 21 . Taken together, both the phenotypic data and transcriptome data point to LSD1 as being functionally linked to the actions of BCL6, a factor required for GC formation due in part to its blockade of plasma cell differentiation and supporting proliferation.
BCL6 mediates LSD1 recruitment to its direct target genes. The data presented above suggest a functional connection between BCL6 and LSD1. To explore this possibility, we first tested whether BCL6 and LSD1 interact. We performed coimmunoprecipitation in diffuse large B cell lymphoma (DLBCL) cells (OCI-Ly1, SUDHL4 and HBL1) and showed that antibodies to LSD1 could precipitate BCL6 and, reciprocally, that antibodies to BCL6 enriched for LSD1 ( Fig. 3a) . We were also able to coimmunoprecipitate LSD1 and BCL6 in lysates from human tonsil-derived GC B cells (Fig. 3b ). Additionally, we performed in vitro histone demethylation assays using LSD1 or BCL6 immunoprecipitates and bulk core histones that bear the various post-transcriptional modifications as substrates. As expected, precipitated LSD1 demethylated H3K4me1 compared to actin control, but BCL6 precipitates also demethylated H3K4me1 in an LSD1-dependent manner, because a specific LSD1 inhibitor blocked BCL6-mediated histone demethylation ( Fig. 3c Articles NATURe ImmUNoLoGy and Supplementary Fig. 3a ). To determine whether the BCL6-LSD1 interaction is direct, we performed protein affinity chromatography with bacterially expressed GST-LSD1 and in vitro-synthetized BCL6. BCL6 was enriched by GST-LSD1 beads even with increasing concentrations of NaCl up to 350 mM, thus indicating direct and robust interaction between these proteins ( Fig. 3d and Supplementary Fig. 3b ).
To determine whether LSD1 is associated with BCL6 on chromatin, we characterized the genomic localization of LSD1 and its relationship to the BCL6 cistrome in GC-derived B cells 
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using ChIP-seq. We identified 6,618 robust LSD1 peaks across replicate experiments (fold change = 5, P < 10 −10 ). Notably, a majority of LSD1 peaks (4,300/6,618, 67%) were lost when BCL6 was depleted, suggesting that BCL6 recruits LSD1 to these sites ( Fig. 3e ). 61% of these BCL6-dependent LSD1 peaks were localized to intronic and intergenic regions, whereas 35% localized to promoters ( Fig. 3e ). Further analysis revealed a significant reduction in BCL6 and LSD1 read counts at these sites after BCL6 knockdown via small interfering RNA (siRNA) ( Fig. 3f,g) . H3K4me1 ChIP-seq in BCL6-knockdown cells or controls showed that gain of this mark was more pronounced at intergenic and intronic BCL6-LSD1 peaks versus promoters ( Fig. 3g ), whereas neighboring regions (− 50 kb) were largely unaltered ( Supplementary Fig. 3c ). We confirmed that genomic loci occupied by BCL6 and LSD1 gained H3K4me1 upon Heat map represents row-based z scores of DESeq2-normalized read counts for differentially expressed genes (FDR < 0.05, fold change > 1.5). b, Heat map of differentially accessible ATAC-seq peaks (FDR < 0.05) from sorted GC B cells from biologically independent immunized Lsd1 fl/fl (n = 2) versus Cγ1-Cre Lsd1 fl/fl (n = 3) mice. Heat map represents row-based z scores of DESeq2-normalized Tn5 insertion counts for each differentially accessible ATAC-seq peak. c, Mean normalized Tn5 insertion signal and heat map of fragment density for loci that gained accessibility (FDR < 0.05) in ATAC-seq analysis of GC B cells sorted from biologically independent immunized Lsd1 fl/fl (n = 2) versus Cγ1-Cre Lsd1 fl/fl (n = 3) mice. d, Genomic distribution of loci that gained accessibility in Lsd1-deficient cells compared to wild-type cells, based on RefSeq. e, Examples of loci that gained accessibility in Lsd1-deficient cells compared to wild-type controls surrounding Prdm1, Cd38 and Stat4. Read density tracks from pooled replicates (n = 2 Lsd1 fl/fl ; n = 3 Cγ1-Cre Lsd1 fl/fl ). f, Cumulative distribution of log 2 fold gene expression change values by proximity of the genes to differentially accessible loci that are closing, opening or remaining stable in Lsd1-deficient cells compared to wild-type controls. Data from biologically independent immunized Lsd1 fl/fl (n = 2) versus Cγ1-Cre Lsd1 fl/fl (n = 3) mice. P value was based on two-sided Kolmogorov-Smirnov test. g, GSEA of genes linked to opening loci in Lsd1-deficient GC B cells versus wild-type cells using ranked gene expression changes induced by Lsd1 depletion in GC B cells in vivo. Normalized enrichment score (NES) and FDR values as implemented by GSEA; based on 10,000 sample permutations. h, Gene pathway analysis of genes that gained accessibility upon Lsd1 deletion (ATAC) or genes upregulated by RNA-seq upon Lsd1 deletion in GC B cells (RNA). Fisher's exact test was used to calculate enrichment P values for each gene set, and q values were calculated based on Benjamini-Hochberg procedure (BH). i, GSEA of genes targeted and repressed by BCL6 through their promoter or genes linked to BCL6-bound proximal enhancers that are upregulated upon BCL6 knockdown in lymphoma cells. Genes were ranked based on decreasing log 2 fold gene expression changes comparing Lsd1-deficient cells to wild-type GC B cells (NES and FDR values as implemented by GSEA, based on 10,000 sample permutations).
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BCL6 knockdown in an additional DLBCL cell line (SUDHL4, Supplementary Fig. 3d ), and we showed that BCL6-LSD1 target sites also gain H3K4me2, another histone mark demethylated by LSD1 ( Supplementary Fig. 3e ).
We next tested whether genes directly bound by LSD1-BCL6 complexes were induced in Cγ1-Cre Lsd1 fl/fl GC B cells. Indeed, genes with intronic or intergenic LSD1-BCL6 complexes were significantly enriched among those upregulated in Cγ1-Cre Lsd1 fl/fl mice ( Fig. 3h ), as exemplified by GFI1 and GPR132 (Fig. 3i ). BCL6-LSD1 targets were significantly enriched for genes linked to enhancers that are poised or lost from NB cells to GC B cells, genes with intronic and intergenic enhancers repressed by BCL6 in primary GC B cells and genes with enhancers activated by Kmt2d ( Fig. 3j ). Genes involved in plasma cell differentiation and GC exit such as B cell receptor signaling, signal transduction, MAPK signaling, cell cycle checkpoints and programmed cell death were also enriched ( Fig. 3j ). These results suggest that LSD1 is a BCL6 corepressor, directly recruited by BCL6 to repress enhancers for genes involved in GC exit, terminal differentiation and proliferation.
LSD1 regulates GC B cell differentiation and BCL6 targets.
To more thoroughly characterize the regulated transcriptome of LSD1, we next performed RNA-seq on human GC-derived lymphoma cells transduced with two LSD1 short hairpin RNAs (shRNAs) ( Fig. 4a ) or a control shRNA. We found that most differentially regulated genes (fold change > 1.5, FDR < 0.05) were upregulated (n = 472, 69%) by both LSD1 hairpins, and 213 genes (31%) were significantly downregulated ( Fig. 4b,c ). Consistent with our murine GC B cell Cγ1-Cre Lsd1 fl/fl RNA-seq studies, significant enrichment for the plasma cell and memory B cell differentiation signature and BCL6 target genes was observed, including the RD2 domaincontrolled transcriptome ( Fig. 4d ). We also observed enrichment for genes controlled by KMT2D through enhancer and promoter H3K4 methylation and the histone acetyltransferase CREBBP, both of which counteract BCL6 as B cells exit the GC reaction by activating enhancers required for terminal differentiation into plasma cells 7-10 ( Fig. 4d ).
We performed gene set enrichment analysis (GSEA) using the plasma/memory cell differentiation gene signature and the Cγ1-Cre Lsd1 fl/fl GC B cell-induced genes and observed enrichment among genes induced by LSD1 shRNA (Fig. 4e ). Confirming the significance of its interaction with BCL6, LSD1 shRNA-induced genes were significantly enriched in BCL6-repressed genes, as were chromatin immunoprecipitation (ChIP)-seq-defined intergenic and intronic LSD1-BCL6 target enhancers ( Fig. 4d,e ). We validated the upregulation of the critical LSD1 target and GC exit gene Irf4 using qPCR ( Fig. 4f ). These data indicate similar functions for LSD1 in murine and human GCs and GC-derived lymphoma cells, linked to BCL6, cell proliferation and GC B cell differentiation pathways.
Noncanonical LSD1 effect in GC B cells and lymphoma.
To understand the LSD1 mechanism of action in GC B cells, we next explored whether its function is mediated through its histonedemethylase activity. We first examined the effect on GC formation of a specific and irreversible LSD1 enzymatic inhibitor (GSK-LSD1; half-maximum effective concentration (EC 50 ) < 10 nM in growth assays using acute myeloid leukemia cell lines) 22, 23 . To this end, we immunized mice with SRBCs and then initiated intraperitoneal injections of GSK-LSD1 inhibitor (0.5 mg/kg) at the highest dose recommended based on limiting thrombocytopenia or vehicle daily for 10 d (Fig. 5a ). In contrast to the striking loss of GCs induced by Lsd1 conditional deletion, the effect of the LSD1 inhibitor on GC B cell populations by flow cytometry and PNA staining was modest, albeit still significant, although LSD1 treatment did not affect splenic GC counts ( Fig. 5a,b ). Unlike this moderate effect on GC B cell populations, LSD1 inhibition in vivo resulted in a significant reduction in Gr1 hi Cd11b + bone marrow-resident mature granulocytes, consistent with its known role in their differentiation 24 ( Supplementary Fig. 4a,b ). LSD1 enzymatic inhibition of a panel of GC-derived lymphoma cell lines had very little effect, even in doses up to 10 μ M, although it was highly effective at these doses against leukemia cells, which are known to be sensitive to LSD1 inhibitors 23 ( Supplementary Fig. 4c ). LSD1 inhibition induced H3K4me2 at LSD1 targets without inducing expression of these targets, in contrast to LSD1 knockdown, which does induce gene expression ( Supplementary Fig. 4e ). However, we confirmed that LSD1 is required to maintain the proliferation of GC-derived lymphoma cells by performing both viability and cell cycle analysis on lymphoma cell lines transduced with LSD1 shRNA ( Supplementary Fig. 4f,g) .
These data suggest that LSD1's mechanism of action in GC B cells involves additional biochemical functions. To address this, we employed a CRISPR-Cas9-based structure-function approach to identify the LSD1 domain(s) that drive(s) the proliferation of GC-derived B cells. CRISPR-Cas9 genome editing frequently generates in-frame mutations instead of insertions or deletions, so that single guide RNAs (sgRNAs) targeting functional domains that sustain cell proliferation and survival are more deleterious to cells than are sgRNAs targeted to nonessential domains 25 . We designed 30 green fluorescent protein (GFP)-expressing sgRNA vectors spanning the different LSD1 protein domains: the N-terminal SWIRM domain (amino acids (aa) 172-271), the C-terminal amino oxidase Experiments were performed at least three times with OCI-Ly1, twice with SUDHL4 and once with HBL1 cells. b, Coimmunoprecipitation of BCL6 and LSD1 in tonsil GC B cell extracts (cropped image). IgG antibody served as a negative control. Experiment was performed twice with similar results. c, H3 and H3K4me1 immunoblot of histone-demethylation reactions (cropped image) with LSD1 and BCL6 immunoprecipitated (IP) from lymphoma B cell extracts and bulk core histone substrates treated with 1 μ M GSK-LSD1 inhibitor or vehicle. Experiment was performed twice with similar results. d, GST pull-down assay using GST-LSD1 or GST alone as control. Purified proteins were incubated with radiolabeled BCL6 and washed with increasing NaCl concentrations. Radioactive signal indicating interaction was captured by fluorography (cropped image). Experiment was performed at least twice with similar results. e, Breakdown of LSD1 significantly depleted peaks after BCL6 knockdown or LSD1 peaks unaltered after BCL6 depletion. Pie chart indicates the genome-wide distribution of BCL6-dependent LSD1 peaks based on RefSeq. f, Fold enrichment of BCL6 and LSD1 ChIP-seq reads normalized to corresponding input in lymphoma cells treated with BCL6 siRNA or non-targeted control siRNA (P values were calculated by one-sided Kolmogorov-Smirnoff test). Top panels show LSD1 peaks that occur in promoter regions (n = 2,557), and bottom panels show LSD1 peaks that are in intronic or intergenic regions (n = 3,503). g, Heat maps showing LSD1, BCL6 and H3K4me1 ChIP-seq peak density surrounding LSD1 peaks in promoters and intergenic/intronic regions shown in e with BCL6 siRNA or non-targeted control siRNA. h, GSEA based on genes ranked by decreasing log 2 fold gene expression changes of Lsd1-deficient cells versus wild-type controls using gene sets linked to BCL6-LSD1 complexes through intronic or intergenic binding (NES and FDR as implemented by GSEA; based on 10,000 sample permutations). i, Examples of LSD1 and BCL6 ChIP-seq tracks surrounding the GFI1 and GPR132 promoter with or without siBCL6 treatment. Experiment was validated more than three times by qChIP. j, Pathway analysis of genes linked to BCL6-dependent LSD1 peaks. P values based on two-sided Fisher's exact test for each gene set; FDR was calculated based on BH.
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NATURe ImmUNoLoGy domain (AOD)-histone demethylase domain (amine oxidase, aa 271-852) and the central protruding 'Tower' domain 26, 27 (aa 417-522) (Fig. 5c ). The LSD1 SWIRM domain, which is often found in chromatin-modifying and chromatin-remodeling complexes, forms interactions with the AOD but lacks DNA-binding properties 26, 27 . The FAD-binding pocket and LSD1 catalytic center are located within the AOD, which accommodates the H3 tail as substrate for demethylation [26] [27] [28] . Finally, the Tower domain is a coiled-coil domain that mediates interactions with CoREST 26, 27 . We initially generated two different OCI-Ly1 subclones that induce Cas9 expression upon doxycycline treatment. The effect of each sgRNA on cell survival was assessed by measurement of the proportion of GFP + cells after doxycycline treatment independently for each of the two Cas9-expressing subclones ( Fig. 5c and Supplementary Fig. 4h 
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For a positive control, we used sgRNAs targeting BCL6, which is essential for lymphoma growth 29, 30 . We confirmed CRISPR-Cas9mediated genetic engineering of the LSD1 locus for our sgRNAs by T7-endonuclease digestion ( Supplementary Fig. 4i ). The most consistently deleterious sgRNAs across clones disrupted the LSD1 Tower domain, which mediates protein-protein interactions 26, 27 ( Fig. 5c and Supplementary Fig. 4h ). Two sgRNAs targeting part of the AOD near its FAD-binding site also dropped out. Taken together, these results suggest that LSD1 GC B cell functions require both the Tower domain and the AOD, and that blocking the enzymatic activity of LSD1 alone is insufficient to fully elicit the LSD1 loss-of-function effect.
To validate this finding, we performed rescue experiments in two lymphoma cell lines (OCI-Ly1 and TMD8) expressing two different LSD1 shRNAs or control shRNA as well as FLAG-tagged LSD1 rescue constructs: wild-type LSD1 (LSD1 wt ), AOD catalytically inactive LSD1 (LSD1 K661A ) 27 , LSD1 lacking the Tower domain (LSD1 ΔTower ) 27 and catalytically inactive LSD1 lacking the Tower domain (LSD1 K661A;ΔTower ). Rescue protein transduction was validated via immunoblot (Fig. 5d ). We found that similar to LSD1 wt , catalytically inactive mutant LSD1 K661A fully rescued the effect of LSD1 depletion on cell growth (Fig. 5e ). However, LSD1 lacking the Tower domain (LSD1 ΔTower ) only partially rescued lymphoma cells, consistent with the CRISPR domain screen (Fig. 5e ). Finally, 
Fig. 5 | LSD1 lymphoma prosurvival effect is mediated through non-catalytic functions. a, Flow cytometry of GC B cell splenocytes, calculated as percent
Fas + GL7 + cells among live B cells (B220 + DAPI -) from biologically independent immunized mice (n = 9 mice per group; mean ± s.d.) treated daily with GSK-LSD1 (0.5 mg/kg) or PBS vehicle and euthanized at 10 d. P values were calculated using a two-sided unpaired t-test, *P < 0.05). Data are representative of three independent experiments. b, Quantification of PNA-stained spleen sections from GSK-LSD1-treated mice versus vehicle-treated mice. Left, fraction of PNA stained area versus the total spleen section area. Middle, GC counts per spleen section. Right, representative IHC images of mouse spleen sections stained with PNA or Ki67 at two magnifications (vehicle versus GSK-LSD1 treated). Each point represents an individual mouse (data are pooled from two independent experiments; n = 18 mice per group; mean ± s.d.; P values were calculated using two-sided unpaired t-test; scale bars, 0.5 mm and 50 μ m on the first and second columns from the left, respectively). c, Fold depletion of % GFP + cells (mean ± s.d.) bearing sgRNAs targeting different parts of the LSD1 open reading frame at day 40 post-doxycycline induction versus day 0. LSD1 protein structure with color-coded protein domains (N terminus, grey; SWIRM, blue; Tower, yellow; AOD, green) (PyMOL). Experiment was performed in n = 4 technical replicates and was further replicated using an independent Cas9-expressing OCI-Ly1 clone ( Supplementary Fig. 4h ). d, Graphical representation of knockdown and rescue FLAG constructs and cropped immunoblot analysis of extracts of lymphoma cells transfected with FLAG-tagged LSD1 rescue constructs: wild-type LSD1 (LSD1 wt ), catalytically inactive LSD1 (LSD1 K661A ), LSD1 lacking the Tower domain (LSD1 ΔTower ) and catalytically inactive LSD1 lacking the Tower domain (LSD1 K661A;ΔTower ), all probed with anti-FLAG. Cells transfected with a Cas9-FLAG construct were used as controls. GAPDH served as protein loading control. Asterisk indicates each FLAG protein. Experiment representative of two blots. e, Viable cell counts (mean ± s.d.) of two lymphoma cell lines (OCI-Ly1 and TMD8 cells in triplicate wells) transfected by control shRNA or two LSD1-targeted shRNAs and rescued with various LSD1 mutant constructs (d), normalized to cells rescued with wild-type LSD1. 
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we wondered whether LSD1 might also be important to the functions of BCL6 in lymphomagenesis. We first observed that LSD1 and BCL6 are concordantly expressed in primary human patients with DLBCL, based on gene expression profiling of two independent patient cohorts 7, 31 (Fig. 6a ).
To determine whether LSD1 is required for BCL6 to induce lymphomagenesis, we crossed Cγ1-Cre Lsd1 fl/fl mice with mice carrying the IμBcl6 allele that mimics BCL6 translocation and causes GC hyperplasia and DLBCL in vivo 32 . To examine whether Lsd1 deletion impairs BCL6-driven GC hyperplasia, we immunized IμBcl6 transgenic mice with conditional deletion of one Lsd1 allele (IμBcl6 Cγ1-Cre Lsd1 fl/+ ) or both Lsd1 alleles (IμBcl6 Cγ1-Cre Lsd1 fl/fl ) and compared them to littermate IμBcl6 animals (IμBcl6 Cγ1-Cre Lsd1 +/+ ). In parallel, we immunized Lsd1 fl/fl and GC-conditional Lsd1-deficient mice (Cγ1-Cre Lsd1 fl/fl ) as controls. All animals manifested unperturbed splenic architecture and disposition of B cells 10 d after immunization ( Supplementary  Fig. 5a ). As previously demonstrated, IμBcl6 mice (IμBcl6 Cγ1-Cre Lsd1 +/+ ) manifested GC hyperplasia (Fig. 6b,f) and higher fractions of GC B cells, based on flow cytometry (Fas + GL7 + B220 + and Fas + CD38 lo B220 + ) ( Fig. 6c-e ). These enlarged IμBcl6 GCs contained increased numbers of Ki67 + cells and more in vivo BrdU labeling, consistent with BCL6-sustained proliferation of the GC compartment (Fig. 6b ). On the contrary, conditional deletion of Lsd1 rescued the IμBcl6-driven GC hyperproliferative phenotype in a dose-dependent manner (Fig. 6d,f) , as loss of one or both Lsd1 allele(s) (IμBcl6 Cγ1-Cre Lsd1 fl/+ or IμBcl6 Cγ1-Cre Lsd1 fl/fl ) yielded significantly reduced GC B cell populations, by flow cytometry and by PNA staining, compared to IμBcl6 Cγ1-Cre Lsd1 +/+ (Fig. 6b-f ). Additionally, IμBcl6 transgenic mice with conditional loss of one or two Lsd1 alleles formed fewer GCs per spleen section compared to IμBcl6 transgenic mice ( Supplementary Fig. 5b ). Unlike IμBcl6 transgenic mice, GC B cells from IμBcl6 Cγ1-Cre Lsd1 fl/+ or IμBcl6 Cγ1-Cre Lsd1 fl/fl transgenic mice were not significantly enriched in replicating (BrdU + ) cells ( Supplementary Fig. 5c ).
To determine whether loss of LSD1 would also impair Bcl6driven lymphomagenesis, we transplanted bone marrow from IμBcl6 Cγ1-Cre Lsd1 +/+ , IμBcl6 Cγ1-Cre Lsd1 fl/fl or Cγ1-Cre Lsd1 fl/fl mice or from Lsd1 fl/fl control mice into lethally irradiated recipient mice. Animals were immunized with SRBCs every 3 weeks to ensure continuous formation of GCs and were regularly monitored for survival and lymphomagenesis. IμBcl6 Cγ1-Cre Lsd1 fl/fl mice manifested significantly delayed lethality compared to IμBcl6 Cγ1-Cre Lsd1 +/+ controls (Fig. 6g ). Lymphomagenesis in IμBcl6 mice is typically associated with massive splenomegaly. Accordingly, most IμBcl6 Cγ1-Cre Lsd1 +/+ mice featured significantly increased spleen weight-to-body weight ratios compared to Cγ1-Cre Lsd1 fl/fl or Cγ1-Cre controls (Fig. 6h) . Remarkably, spleens of IμBcl6 Cγ1-Cre Lsd1 fl/fl were indistinguishable from those of controls and were significantly reduced compared to those of IμBcl6 Cγ1-Cre Lsd1 +/+ mice (Fig. 6h ).
Pathological analysis of spleens, livers and other organs collected upon euthanasia revealed that most IμBcl6 Cγ1-Cre Lsd1 +/+ mice had developed lymphoma with complete effacement of lymphoid organs ( Fig. 6g and Supplementary Fig. 5d ). These contained large, atypical B220 + lymphoid cells with centroblast and immunoblast features. Moreover, IμBcl6 Cγ1-Cre Lsd1 +/+ mice featured invasive lymphoma infiltrates in their livers within centrilobular spaces and with sinusoid spreading, as well as in lungs and kidneys. Conversely, in IμBcl6 Cγ1-Cre Lsd1 fl/fl mice, lymphoid structures were mainly preserved with minimal effacement and no parenchymal infiltration, with only some large B220 + lymphoid elements seen within GCs and/or ectopically scattered in the lymphoid organs. Taken together, these data suggest that LSD1 is required for BCL6 to drive malignant transformation of GC B cells.
Discussion
Dampening expression of genes induced by T cell help is believed to be important for B cells to undergo immunoglobulin affinity maturation without premature interruption 1 . Herein, we report that LSD1, a FAD-dependent demethylase, is essential for GC formation, and that LSD1 loss causes reactivation of GC-repressed enhancers, increased chromatin accessibility and gene upregulation, thus implicating that this chromatin modifier as a critical epigenetic regulatory factor in the GC reaction. LSD1 loss of function caused failure to repress genes induced by T cell help that encode molecules involved in GC exit and terminal differentiation, such as IRF4, XBP1 and PRDM1, which may explain why Lsd1-deficient GCs are short-lived and fail to expand, preventing the formation of fully fledged GCs. In addition, LSD1 repressed several genes encoding molecules involved in B cell signaling interactions with T cells, including CD80 (the CLTA4 receptor), CXCR3, Stat4, and the CD155 ligands TIGIT and CD226. Failure to proliferate could also be linked to upregulation of genes encoding molecules that inhibit cell-cycle progression. One of these genes, encoding the the orphan G protein-coupled receptor Gpr132, was shown to arrest cell-cycle progression in B cells downstream of IKZF 20 .
LSD1 requires transcription factors for its recruitment to chromatin, and in GC B cells, BCL6 accounts for a large fraction of LSD1-binding sites in the genome. Recruitment of LSD1 is clearly important for BCL6 to repress its direct targets. However, we emphasize that LSD1's histone-demethylase function alone is not sufficient for its actions in GC B cells, as we observed that the LSD1 Tower domain is required and essential for its actions in this cellular context. This finding suggests that recruitment of the CoREST complex (which also contains HDAC1/2) 33,34 is critically required for LSD1 to mediate the repressive chromatin state and downstream biological effects in GC B cells. Notably, among all monoamine oxidases, including the AOD-containing homolog Lsd2 (Kdm1B), this coiled coil Tower domain is unique to LSD1, which may explain the apparent lack of compensatory effects of Kdm1B in Lsd1-deficient GC B cells 35 . These findings are in sharp contrast to LSD1's mechanisms in myeloid leukemia, in which LSD1's catalytic activity was shown to be crucial 16, 23, 36, 37 . LSD1 inhibitors did cause a modest reduction in GC B cells, suggesting that loss of enzymatic activity might be slightly deleterious in primary GC B cells. However, this effect may also be due to perturbation of LSD1 function in other GC cell types, such as GC follicular helper T cells. Indeed, there is evidence that LSD1 plays an important role in T cell development 38 . LSD1 is also known to act as a corepressor for PRDM1 (ref. 39 ), suggesting that LSD1 binds to and enables BCL6 to maintain the GC phenotype and may then switch to assist PRDM1 in inducing the plasma cell phenotype once BCL6 is downregulated.
Finally, consistent with our finding that LSD1 is an important BCL6 co-factor, our data indicate that LSD1 plays a critical role in lymphomagenesis, since it is required for this canonical lymphoma oncogene to induce malignant transformation. Although it is tempting to consider enzymatic inhibitors of LSD1 as a potential therapeutic strategy in lymphomas, these drugs are not sufficient to antagonize its actions. Instead, novel classes of inhibitors may need to be developed that could destabilize LSD1's protein interactions, in addition to its enzymatic activity.
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Methods
Mice. Conditional Lsd1-deficient mice (loxP-flanked Lsd1 allele, Lsd1 fl/fl ) were purchased from the Jackson laboratory (023969). By crossing Lsd1 fl/fl with the transgenic Cγ1-Cre strain (The Jackson Laboratory, 010611), we generated heterozygous Cγ1-Cre Lsd1 +/fl mice, which were crossed to yield Cγ1-Cre Lsd1 fl/fl mice. For controls, we used Cγ1-Cre-negative Lsd1 fl/fl littermates. B cell conditional Lsd1 deletion was generated by crossing Lsd1 fl/fl mice with CD19-Cre mice (Jackson Laboratory, 006785), where Cre is expressed from the pre-B cell stage. Mice were used for assessment of GC formation induced by immunization with SRBCs or affinity maturation by immunization with NP-CGG [28] [29] [30] . We also used IμBcl6 mice (obtained from R. Dalla-Favera, Columbia University 32 ) to generate IμBcl6 Cγ1-Cre Lsd1 fl/fl mice by crossing with Cγ1-Cre Lsd1 fl/fl mice. These mice were used for GC formation assays or as bone marrow donors for transplantation into C57BL/6 recipients. Animal care and all experiments were performed in strict compliance with the institutional guidelines and protocols of Weill Cornell Medicine and Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee, the Association for Assessment and Accreditation of Laboratory Animal Care International and in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals.
Germinal center formation experiments and flow cytometry.
Age-and sexmatched C57BL/6 mice (8-12 weeks old) were immunized intraperitoneally with 0.5 ml of a 2% SRBC suspension in PBS (Cocalico Biologicals) and euthanized after 10 d. Single-cell suspensions from mouse spleens were separated by Ficoll gradient centrifugation and stained using fluorescent-labeled anti-mouse: PE-Cy7 anti-B220 (eBioscience, 25-0452, dilution 1:500), APC anti-CD38 (eBioscience,17-0381, dilution 1:500), APC anti-B220 (BD Biosciences, 553092, dilution 1:500), PE anti-FAS (BD Biosciences, 554258, dilution 1:500), FITC anti-GL7 (BD Biosciences, 553666, dilution 1:500), BV421 anti-CD138 (BioLegend, 142507, 1:500), FITC anti-κ (BioLegend, 409509, 1:500) or APC-Cy7 anti-κ (BioLegend, 409503, 1:500), PE-Cy7 anti-CD11b (BioLegend, 101216, dilution 1:300) and APC-Cy7 anti-Gr1 (108424, dilution 1:300). DAPI was used for the exclusion of dead cells. When needed, cells were fixed and permeabilized using the BD Cytofix/Cytoperm Kit (554714, BD Biosciences). For cell cycle analysis, cells were stained in vitro by addition of BrdU (10 μ M) for 20 min. 7AAD was used to determine DNA content in cell cycle analysis, along with V450 anti-BrdU staining (BD Pharmingen, V450, dilution: 1:50). For treatment with the LSD1 inhibitor GSK-LSD1, mice were injected intraperitoneally with drug or PBS vehicle, starting the day after SRBC injection and administered daily at a concentration of 50 mg/kg per day until they were euthanized. For RNA-seq studies of sorted GC B populations, mononuclear splenocytes were enriched for B cells using magnetic cell separation (AutoMACS) with CD45R (B220) beads (130-049-501, Miltenyi Biotec). Cells were then stained with APC anti-B220 (553092, dilution 1:500), BV-421 anti-GL7 (562967, BD Biosciences, dilution 1:500) and PE-Cy7 anti-FAS (557653, BD Biosciences, dilution 1:500) and were sorted on a BD FACSAria III instrument. Flow cytometry strategies are summarized in Supplementary Fig. 6 .
Bone marrow transplantation.
For murine bone marrow (BM) transplantation assays, BM cells from 6-to 8-week-old male donors were harvested. 1 × 10 6 BM cells of each type were tail vein injected in female C57BL/6 mice lethally irradiated with two doses of 450 rad. All mice were monitored until any one of several criteria for euthanizing were met, including severe lethargy, > 10% body weight loss and palpable splenomegaly that extended across the midline. In our survival analysis, we censored three mice that died less than 1 month after bone marrow transplantation and lacked distinct pathological features due to failed BM engraftment, one animal that was euthanized due to tail necrosis and one mouse that was euthanized due to dermatitis, based on Research Animal Resource Center recommendations. Immunohistochemistry. Tissues were fixed in 10% formalin and embedded in paraffin at the Laboratory of Comparative Pathology at MSKCC. Paraffin sections were dewaxed in xylene and hydrated into graded alcohols. Immunohistochemistry was performed on Leica Bond RX using the Bond Polymer Refine Detection Kit (Cat. No. DS9800). Deparaffinized slides were antigen retrieved depending on the target epitope, and endogenous peroxidase (HRP) activity was blocked by immersing the slides in 1% hydrogen peroxide in PBS for 15 min. Slides were initially incubated with primary antibodies to BrdU (Abcam, ab6326, diluted 1:500; antigen retrieval: heat mediated, EDTA, pH 9.0), Ki67 (Vector VP-K451, dilution 1:100; antigen retrieval: heat mediated, EDTA, pH 9.0), B220 (BD Bioscience, 550286, diluted 1:200; antigen retrieval: heat mediated with 10 mM citrate buffer, pH 6.0) and LSD1 (abcam 17721, diluted 1:1000; antigen retrieval: heat mediated with 10 mM citrate buffer, pH 6.0). After washing, slides were incubated with species-specific biotinylated secondary antibodies and then avidin-HRP or avidin-AP incubation. Biotin-conjugated PNA (Vector Laboratories B-1075, dilution 1:250) was used to identify germinal centers. Antibody reaction was visualized with DAB (3-3′ diaminobenzidine, Sigma, Cat. No. D8001) or Vector Blue (Vector Laboratories) and then counterstained with hematoxylin if necessary. For LSD1 staining, we used BCIP/NBT chromogen to develop. Tissue sections were dehydrated in graded alcohols, cleared in xylene and mounted. Slides were scanned using a Zeiss Mirax Slide Scanner, and photomicrographs were examined with Panoramic Viewer software. ImageJ 1.44o software (NIH) was used to quantify GC areas.
Coimmunoprecipitation. Lysates from DLBCL cells were prepared using 25 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.1% SDS lysis buffer with protease inhibitors (Roche). 5 μ g of antibodies to BCL6 (Santa Cruz N3, sc-858) or LSD1 (abcam 17721) or IgG control antibodies were added to precleared lysates and incubated overnight at 4 °C with rocking. Protein A beads (Roche) were added for 2 h at 4 °C with gentle agitation, washed four times (25 mM Tris, pH 7.4, 200 mM NaCl, 0.5% NP-40, 0.1% SDS) and then boiled in 1× LDS sample buffer (Thermo Fisher #NP0007) supplemented with 5% β -mercaptoethanol, and supernatant was resolved by polyacrylamide gel electrophoresis (SDS-PAGE). For histonedemethylation assays, immunoprecipitated complexes were washed on-bead and incubated with 1 μ g bulk histones (H4524, Sigma) in histone demethylase buffer (50 mM Tris HCl, 50 mM KCl, 5 mM MgCl 2 , 0.5% BSA, 5% glycerol) overnight 11 . Reactions were denatured and resolved by 18% SDS-PAGE.
GST pull-down. Radiolabeled BCL6 was generated by TnT T7 Quick Transcription/Translation system (Promega) according to the manufacturer's protocol supplemented with 0.02 mCi EasyTag l-[ 35 S]-methionine (Perkin Elmer). GST and GST-LSD1 fusion pGEX-based vectors were transformed in BL21(DE3) competent Escherichia coli. Bacterial cultures were grown to OD 600 0.5-0.6, and then protein expression was induced with 1 mM IPTG for 3 h at 37 °C with shaking. Bacteria were pelleted, resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100) supplemented with DNase I (5 μ g/ml) and lysozyme (20 μ g/ml) and incubated for 30 min on ice and then spun for 30 min at 21,000g. Bacterial lysates were incubated with glutathione Sepharose beads (GE Healthcare) at 22 °C for 1 h with rocking, then washed 5× with PBS. Finally, GST or GST-LSD1 proteins were eluted with Glutathione Elution Buffer (50 mM Tris-HCl pH 8, 10 mM reduced glutathione). After gel-based quantification, 5 μ g of purified GST-tagged protein was bound to glutathione Sepharose beads in binding buffer for 1 h at 4 °C (20 mM HEPES, pH7.5, 150 mM KCl, 25 mM MgCl 2 , 10 mM DTT, 0.1 mM EDTA, 0.15% NP-50) and, after multiple washes, 20 μ l of the radiolabeled in vitro transcription/translation reaction containing 35 S-labeled BCL6 protein bait was added to each sample and incubated 1 h at 4 °C with rocking. After washing the beads with binding buffer with increasing-stringency salt concentrations, beads were boiled in 1× LDS sample buffer (Thermo Fisher #NP0007) supplemented with 5% β -mercaptoethanol and supernatant was resolved by SDS-PAGE. Gels were then fixed (10% glacial acetic acid, 20% methanol (v/v) in water), incubated in liquid autoradiography enhancer for 1 h (EN3HANCE, Perkin Elmer), vacuum dried (70 °C, 3 h) and developed by autoradiography after exposing to film for 24 h at − 80 °C.
Immunoblotting. Lysates of DLBCL lymphoma cell lines and isolated cell populations were prepared using 25 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.1% SDS and complete protease inhibitor cocktail (Roche) lysis buffer. Protein lysates were resolved by SDS-PAGE, transferred to PVDF membrane and probed with primary antibodies to the following: LSD1 (Santa Cruz, 1B2E5, sc-53875), FLAG (F1804, M2, Sigma), GAPDH (Santa Cruz, FL-335, sc-25778), actin (sc-81760). Membranes were then incubated with corresponding HRP-conjugated secondary antibodies, and signal was detected using enhanced chemiluminescence (ChemiDoc Touch, Bio-Rad Laboratories). Densitometry values were obtained using ImageJ 1.44o software (NIH).
ELISA. Mice were immunized by intraperitoneal injection of NP-CGG [28] [29] [30] (200 μ g) in alum and were boost-immunized with the same dose 21 d after the primary immunization. Serum samples were collected at 26 d post primary NP-CGG immunization, and the abundance of NP hapten-specific immunoglobulin titers was analyzed by ELISA. Sera were tested for binding of NP-specific antibodies to low-haptenated BSA (NP 7 -BSA)-versus high-haptenated BSA (NP 30 -BSA)coated plates using HRP-conjugated antibodies (SouthernBiotech, dilution 1:500). Optical density (OD) at 450 nm was measured in a plate reader (BioTek), and the absorbance ratio was calculated by dividing the mean OD of NP 7 -BSA-coated wells by the mean OD of NP 30 -BSA-coated wells. Titers were calculated by logarithmic interpolation of the dilutions with readings immediately above and immediately below a chosen OD 450 threshold equal to two-fold of background OD 450 , as previously described 40 .
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